Presenting PromarkerD clinical validation results with US Big Pharma
The American Diabetes Association’s 80th Scientific Sessions was a virtual conference (June 12-16) gathering the world leaders in diabetes, complications and therapeutics.
Proteomics presented PromarkerD clinical validation results in collaboration with a US Big Pharma company at the world’s leading diabetes conference on June 13, 10am CT.
Validation of the PromarkerD Test for Predicting Renal Decline in Type 2 Diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Kirsten E. Peters (1,2), Jialin Xu (3), Scott D. Bringans (1), Wendy A. Davis (2), Timothy M.E. Davis (2), Michael K. Hansen (3), Richard J. Lipscombe (1)
1: Proteomics International, Perth, Western Australia, Australia.
2: Medical School, University of Western Australia, Crawley, Western Australia, Australia.
3: Janssen Research & Development, LLC, Spring House, PA, USA.
Poster 1118-P presented in category 12-G Clinical Therapeutics/New Technology – SGLT Inhibitors